

Novavax to Participate in BofA Securities 2024 Health Care Conference

May 13, 2024

GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.

Conference Details:

Fireside Chat

Date:	Wednesday, May 15, 2024
Time:	3:00 – 3:30 p.m. Pacific Daylight Time (PDT)
Location:	Encore Hotel in Las Vegas, NV
Moderator:	Alec Stranahan, PhD, Equity Research – U.S. Biopharma
Novavax participant:	John C. Jacobs, President and Chief Executive Officer

Conference

Event:	Investor Meetings
Date:	Wednesday, May 15, 2024

Recordings

A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and [LinkedIn](#) for more information.

Contacts:

Investors

Erika Schultz
240-268-2022
ir@novavax.com

Media

Giovanna Chandler
202-709-5563
media@novavax.com

SOURCE Novavax, Inc.